Beyond Air, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Beyond Air, Inc. on August 9, 2024, covering events occurring on August 6 and August 8, 2024. The filing primarily addresses the announcement of financial results for the first quarter ended June 30, 2024, a Nasdaq listing deficiency notice, and executive leadership changes.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended June 30, 2024. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Listing Status
On August 8, 2024, the Company received a notice from Nasdaq stating that its common stock bid price had been below the minimum requirement of $1.00 per share for 30 consecutive business days. The Company has 180 calendar days (until February 4, 2025) to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to comply may result in delisting, though the Company may seek an additional 180-day period by meeting other listing standards, potentially via a reverse stock split.
Management Commentary and Personnel Changes
On August 6, 2024, Amir Avniel was appointed Chief Executive Officer of NeuroNOS Israel Limited, overseeing the Company's autism spectrum disorder program. Concurrently, Mr. Avniel tendered his resignation from the Board of Directors and as Chief Business Officer of Beyond Air, Inc., effective August 15, 2024. He will remain President of the Beyond Air Ltd. subsidiary. The resignations were voluntary and not due to any disagreement with the Company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2024 financial figures (revenue, net loss, cash position) not included in this summary.
- Monitor the daily closing bid price of XAIR stock to assess progress toward the $1.00 Nasdaq compliance threshold.
- Verify the Company's plan to regain listing compliance, including the potential timing and ratio of a reverse stock split if the bid price does not recover naturally.
- Confirm the operational impact of Amir Avniel's transition from Chief Business Officer to CEO of the NeuroNOS Israel subsidiary.